Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals varying in fat and carbohydrate and their association with hunger and the phases of satiety

What Was Tested

This randomized controlled trial paper looks at Ghrelin.

The purpose of this study was first to compare the postprandial profiles of ghrelin, glucagon-like peptide 1 (GLP-1), and peptide YY (PYY) after isoenergetic meals differing in fat and carbohydrate content and second to examine the relationships between ghrelin, GLP-1, and PYY with hunger, fullness, and energy intake.

Why It Was Studied

The relationship between postprandial peptides at circulating physiological levels and short-term appetite control is not well understood.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The participants were 16 healthy overweight/obese adults.

How the Study Was Run

The design is described as randomized and crossover.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the participants took both Ghrelin and the comparison in turn, acting as their own control.

Plasma was collected before and periodically after the meals for 180 minutes, after which time ad libitum food was provided.

Simultaneous ratings of hunger and fullness were tracked for 180 minutes through phases identified as early (0-60 minutes) and late (60-180 minutes) satiety.

This study was conducted at the Psychobiology and Energy Balance Research Unit, University of Leeds.

What Was Measured

The relationship between postprandial peptides at circulating physiological levels and short-term appetite control is not well understood.

PubMed files the paper under topics including Appetite Regulation, Biomarkers, Body Mass Index, Dietary Carbohydrates, Dietary Fats, Energy Intake and England.

What This Means in Plain Language

The paper is a randomized and crossover study of Ghrelin.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Ghrelin compound page, all human trials.